ImmunoCellular Therapeutics Debt To Equity vs. Cash Flow From Operations
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
For ImmunoCellular Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmunoCellular Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmunoCellular Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmunoCellular Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmunoCellular Therapeutics over time as well as its relative position and ranking within its peers.
ImmunoCellular |
ImmunoCellular Therapeutics Cash Flow From Operations vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ImmunoCellular Therapeutics's current stock value. Our valuation model uses many indicators to compare ImmunoCellular Therapeutics value to that of its competitors to determine the firm's financial worth. ImmunoCellular Therapeutics is currently regarded as number one stock in debt to equity category among its peers. It is rated second overall in cash flow from operations category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunoCellular Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunoCellular Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.ImmunoCellular Cash Flow From Operations vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
ImmunoCellular Therapeutics |
| = | 0.39 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
ImmunoCellular Therapeutics |
| = | (2.31 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
ImmunoCellular Cash Flow From Operations Comparison
ImmunoCellular Therapeutics is currently under evaluation in cash flow from operations category among its peers.
ImmunoCellular Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ImmunoCellular Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmunoCellular Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of ImmunoCellular Therapeutics' change in net profit over the period of time. It can combine multiple indicators of ImmunoCellular Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
ImmunoCellular Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ImmunoCellular Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmunoCellular Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmunoCellular Therapeutics' important profitability drivers and their relationship over time.
Use ImmunoCellular Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoCellular Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoCellular Therapeutics will appreciate offsetting losses from the drop in the long position's value.ImmunoCellular Therapeutics Pair Trading
ImmunoCellular Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to ImmunoCellular Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunoCellular Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunoCellular Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunoCellular Therapeutics to buy it.
The correlation of ImmunoCellular Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunoCellular Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunoCellular Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunoCellular Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ImmunoCellular Therapeutics position
In addition to having ImmunoCellular Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Apparel Thematic Idea Now
Apparel
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Apparel theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Apparel Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |